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Aims and objectives
Adverse reactions to intravenous contrast media (CM) agents are uncommon, although
relevant due to the growing number of radiologic examinations that use iodinated contrast
agents [1].
Reaction may be patient related and risks of acute adverse reaction is usually searched
before administration. Reactions are classified according to guidelines in non renal, renal
and miscellaneous [2]. Most common non-renal reactions are acute allergic reactions
that are usually classified in mild, moderate and severe. In order to reduce acute allergic
reactions patient- risk factors are deeply screened before administration according to
ESUR guideline [2] as: history of previous acute reaction to contrast media; history of
asthma, and history of allergies requiring medical treatment [1,2]. For these reasons
ESUR guidelines and some literature recommend premedication with steroids if the
examination with CM is considered clinically necessary [3].
We evaluated number and prevalence of adverse contrast reaction using different
contrast compound and its natural history in our population, specifically looking to cases
of new contrast compound administration was considered clinically necessary.
Methods and materials
We retrospectively studied number of adverse contrast reaction in MDCT in our
population of 43680 patients submitted to MDCT with administration of CM
73 patients, who had an adverse allergic reaction to iodinated CM, were analysed from
January 2011 to May 2014; 1 patient (0,002%) had a severe allergic reaction requiring
resuscitation manoeuvre and was exclude from the sample. 72 (0,164%) patients had a
mild or moderate adverse reactions (Fig. 1). Symptoms referred by patients or annotated
in patient flow chart are listed in Fig. 2. Different contrast compound responsible for mild
or moderate reaction are listed in Fig. 3.
Images for this section:
Page 3 of 5
Fig. 1: number of mild or moderate reactions to iodinated CM
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Fig. 2: Contrast media compound used in mild or moderated reaction.
Fig. 3: Symptoms referred by patients with reaction
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Results
MDCT with contrast because was considered clinically necessary and repeated after
a premedication according with ESUR guidelines (prednisolone 30 mg orally given 12
and 2 hours before contrast medium), in 20 patients (27,39%) using a different contrast
compounds. No allergic adverse effect was observed in this population.
Conclusion
Recommended premedication regimen and change of contrast compound may increase
safety of administration and reduce allergic reactions in case of repeated MDCT with CM
and history of previous mild or moderate allergic reactions.
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